Valuation: Insmed Incorporated

Market Cap 23.86B 21.4B 19.56B 17.85B 33.64B 2,243B 34.7B 236B 94B 1,197B 89.56B 87.64B 3,778B P/E 2026 *
-65.7x
P/E 2027 * 146x
Enterprise Value 23.35B 20.94B 19.14B 17.47B 32.91B 2,195B 33.95B 231B 91.97B 1,171B 87.63B 85.75B 3,697B EV / Sales 2026 *
12.5x
EV / Sales 2027 * 7.7x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+5.19%
1 week+2.52%
Current month+1.62%
1 month+10.18%
3 months+15.54%
6 months-17.95%
Current year-34.27%
1 week 102.69
Extreme 102.69
114.65
1 month 92.62
Extreme 92.625
116.37
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.19
Extreme 11.19
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Chief Tech/Sci/R&D Officer 62 2019-12-18
Chief Operating Officer 57 2019-11-13
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Director

-25,000 0.0114%
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
+5.19%+2.52%-38.78%+360.38% 23.86B
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.42%+12.77%+75.21% 57.24B
-1.34%+3.53%+23.22%+101.58% 57.62B
+2.62%-1.17%+29.37%+37.84% 43.65B
+5.09%+9.53%+26.62%+121.44% 44.03B
+8.24%+1.06%+224.03%+767.69% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-6.89%+91.79%+74.60% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.80%+1.76%+48.78%+166.86% 42.83B
Weighted average by Cap. +0.34%+2.16%+48.78%+150.44%

Financials

2026 *2027 *
Net sales 1.86B 1.67B 1.53B 1.39B 2.62B 175B 2.71B 18.39B 7.33B 93.36B 6.99B 6.84B 295B 2.99B 2.68B 2.45B 2.24B 4.22B 281B 4.35B 29.57B 11.79B 150B 11.23B 10.99B 474B
Net income -357M -321M -293M -267M -504M -33.59B -520M -3.53B -1.41B -17.92B -1.34B -1.31B -56.58B 174M 156M 142M 130M 245M 16.32B 253M 1.72B 684M 8.71B 652M 638M 27.5B
Net Debt -514M -461M -422M -385M -725M -48.36B -748M -5.08B -2.03B -25.8B -1.93B -1.89B -81.46B -826M -741M -677M -618M -1.16B -77.68B -1.2B -8.16B -3.26B -41.45B -3.1B -3.04B -131B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-11-06 US$114.41 +5.19% 3,371,252
26-11-05 US$108.76 -1.13% 2,616,308
26-11-04 US$110.00 +5.32% 4,944,543
26-11-03 US$104.44 -4.46% 6,216,187
26-11-02 US$109.31 -2.90% 4,241,735
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
114.40USD
Average target price
194.18USD
Spread / Average Target
+69.73%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insmed Incorporated
  1. Stock Market
  2. Stocks
  3. INSM Stock